KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Share-based Compensation (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Share-based Compensation data on record, last reported at $70.9 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 0.95% year-over-year to $70.9 million; the TTM value through Dec 2025 reached $291.1 million, up 17.37%, while the annual FY2025 figure was $291.1 million, 17.37% up from the prior year.
  • Share-based Compensation reached $70.9 million in Q4 2025 per JAZZ's latest filing, down from $88.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $88.1 million in Q3 2025 and bottomed at $34.5 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $58.9 million, with a median of $56.7 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: surged 75.38% in 2021, then decreased 14.0% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $53.1 million in 2021, then rose by 15.89% to $61.6 million in 2022, then dropped by 14.0% to $52.9 million in 2023, then soared by 32.58% to $70.2 million in 2024, then rose by 0.95% to $70.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $70.9 million in Q4 2025, $88.1 million in Q3 2025, and $64.5 million in Q2 2025.